Bioequivalence of two tablet formulations of clopidogrel in healthy argentinian volunteers: A single-dose, randomized-sequence, open-label crossover study

Clinical Therapeutics

Volumn 32, Issue 1, 2010, Pages 161-170

  Di Girolamo, Guillermo ^a   Czerniuk, Paola ^b   Bertuola, Roberto ^b   Keller, Guillermo A ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Centro de Medicina Integral SRL   (Argentina)

Author keywords

bioequivalence; clopidogrel; pharmacokinetics

Indexed keywords

ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DRUG DERIVATIVE; GENERIC DRUG; TICLOPIDINE;

ADULT; AREA UNDER THE CURVE; ARGENTINA; ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; TABLET; TANDEM MASS SPECTROMETRY;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; ARGENTINA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DRUGS, GENERIC; FEMALE; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; REFERENCE VALUES; TABLETS; TANDEM MASS SPECTROMETRY; THERAPEUTIC EQUIVALENCY; TICLOPIDINE; YOUNG ADULT;

MLCS; MLOWN;

EID: 77952299363     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.01.010     Document Type: Article

References (66)

1. Sugidachi, A, Asai, F, Ogawa, T, et al. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol. 129 (2000), 1439–1446.
2. Cattaneo, M, The platelet P2Y receptors as targets for new antithrombotic drugs. J Thromb Haemost. 1 (2003), 1133–1135.
3. Savi, P, Herbert, JM, Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost. 31 (2005), 174–183.
4. Goto, S, Tamura, N, Ishida, H, Ruggeri, ZM, Dependence of platelet thrombus stability on sustained glycoprotein IIb/IIIa activation through adenosine 5′-diphosphate receptor stimulation and cyclic calcium signaling. J Am Coll Cardiol. 47 (2006), 155–162.
5. Yusuf, S, Zhao, F, Mehta, SR, et al., Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation [published corrections appear in N Engl J Med. 2001;345:1506 and N Engl J Med. 2001;345:1716]. N Engl J Med. 345 (2001), 494–502.
6. Braunwald, E, Antman, EM, Beasley, JW, et al., American College of Cardiology/American Heart Association Committee on the Management of Patients With Unstable Angina. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction—summary article: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 40 (2002), 1366–1374.
7. Steinhubl, SR, Berger, PB, Mann, JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial [published correction appears in JAMA. 2003;289:987]. JAMA. 288 (2002), 2411–2420.
8. Smith, SC Jr, Feldman, TE, Hirshfeld, JW Jr, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines, ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation. 113 (2006), e166–e286.
9. Diener, HC, Ringleb, PA, Savi, P, Clopidogrel for the secondary prevention of stroke. Expert Opin Pharmacother. 6 (2005), 755–764.
10. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 348 (1996), 1329–1339.
11. Fox, KA, Chelliah, R, Clopidogrel: An updated and comprehensive review. Expert Opin Drug Metab Toxicol. 3 (2007), 621–631.
12. Taubert, D, Kastrati, A, Harlfinger, S, et al. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost. 92 (2004), 311–316.
13. von Beckerath, N, Taubert, D, Pogatsa-Murray, G, et al. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Chosen Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation. 112 (2005), 2946–2950.
14. Mullangi, R, Srinivas, NR, Clopidogrel: Review of bioanalytical methods, pharmacokinetics/pharmacodynamics, and update on recent trends in drug-drug interaction studies [published correction appears in Biomed Chromatogr. 2009;23:334]. Biomed Chromatogr. 23 (2009), 26–41.
15. McEwen, J, Strauch, G, Perles, P, et al. Clopidogrel bioavailability: Absence of influence of food or antacids. Semin Thromb Hemost. 25:Suppl 2 (1999), 47–50.
16. Deray, G, Bagnis, C, Brouard, R, et al. Clopidogrel activities in patients with renal function impairment. Clin Drug Investig. 16 (1998), 319–328.
17. Slugg, PH, Much, DR, Smith, WB, et al. Cirrhosis does not affect the pharmacokinetics and pharmacodynamics of clopidogrel. J Clin Pharmacol. 40 (2000), 396–401.
18. Savi, P, Combalbert, J, Gaich, C, et al. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost. 72 (1994), 313–317.
19. Pereillo, JM, Maftouh, M, Andrieu, A, et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos. 30 (2002), 1288–1295.
20. Clarke, TA, Waskell, LA, The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos. 31 (2003), 53–59.
21. Caplain, H, Donat, F, Gaud, C, Necciari, J, Pharmacokinetics of clopidogrel. Semin Thromb Hemost. 25:Suppl 2 (1999), 25–28.
22. Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070244.pdf Accessed October 13, 2009.
23. US Food and Drug Administration. Guidance for Industry. Statistical approaches to establishing bioequivalence. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070244.pdf Accessed October 15, 2009.
24. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice E6(R1). Current Step 4 version, dated 10 June 1996 (including the Post Step 4 corrections) http://www.ich.org/LOB/media/MEDIA482.pdf Accessed October 15, 2009.
25. Shin, BS, Yoo, SD, Determination of clopidogrel in human plasma by liquid chromatography/tandem mass spectrometry: Application to a clinical pharmacokinetic study. Biomed Chromatogr. 21 (2007), 883–889.
26. Ritschel, WA, Kearns, GL, Handbook of Basic Pharmacokinetics—Including Clinical Applications, 6th ed., 2004, American Pharmacists Association, Washington, DC.
27. Conover, WJ, (eds.) Practical Nonparametric Statistics, 2nd ed., 1980, Wiley, New York, NY.
28. Hsuan, FC, Estimating treatment means in a mixed-effect ANOVA model for bioequivalence studies. Biometrics. 49 (1993), 703–713.
29. Chow, SC, Liu, JP, Design and Analysis of Bioavailability and Bioequivalence Studies, 2nd ed, 2000, Marcel Dekker, New York, NY.
30. Schuirmann, DJ, A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 15 (1987), 657–680.
31. Anderson, S, Hauck, WW, A new procedure for testing equivalence in comparative bioavailability and other clinical trials. Comm Statist Theory Methods. 12 (1983), 2663–2692.
32. Bertrand, ME, Rupprecht, HJ, Urban, P, Gershlick, AH, CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation. 102 (2000), 624–629.
33. Yusuf, S, Mehta, SR, Zhao, F, et al., Clopidogrel in Unstable angina to prevent Recurrent Events Trial Investigators. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation. 107 (2003), 966–972.
34. Richter, W, Erenmemisoglu, A, Van der Meer, MJ, et al. Bioequivalence study of two different clopidogrel bisulfate film-coated tablets. Arzneimittelforschung. 59 (2009), 297–302.
35. El Ahmady, O, Ibrahim, M, Hussein, AM, Bustami, RT, Bioequivalence of two oral formulations of clopidogrel tablets in healthy male volunteers. Int J Clin Pharmacol Ther. 47 (2009), 780–784.
36. Kim, SD, Kang, W, Lee, HW, et al. Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: A randomized, open-label, crossover study in healthy Korean male subjects. Clin Ther. 31 (2009), 793–802.
37. Filipe, A, Almeida, S, Franco Spinola, AC, et al. Single-dose randomized, open-label, 2-way crossover bioequivalence study of clopidogrel 75 mg tablet in healthy volunteers under fasting conditions. Int J Clin Pharmacol Ther. 47 (2009), 187–194.
38. Lainesse, A, Ozalp, Y, Wong, H, Alpan, RS, Bioequivalence study of clopidogrel bisulfate film-coated tablets. Arzneimittelforschung. 54 (2004), 600–604.
39. Reist, M, Roy-de Vos, M, Montseny, JP, et al. Very slow chiral inversion of clopidogrel in rats: A pharmacokinetic and mechanistic investigation. Drug Metab Dispos. 28 (2000), 1405–1410.
40. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Tripartite Harmonised Guideline. Impurities in New Drug Products Q3B(R2). Current Step 4 version, 2 June 2006 http://www.ich.org/LOB/media/MEDIA421.pdf Accessed October 15, 2009.
41. Gomez, Y, Adams, E, Hoogmartens, J, Analysis of purity in 19 drug product tablets containing clopidogrel: 18 Copies versus the original brand. J Pharm Biomed Anal. 34 (2004), 341–348.
42. Takahashi, M, Pang, H, Kawabata, K, et al. Quantitative determination of clopidogrel active metabolite in human plasma by LC-MS/MS. J Pharm BiomedAnal. 48 (2008), 1219–1224.
43. Petersen, KU, Relevance of metabolic activation pathways: The example of clopidogrel and prasugrel. Arzneimittelforschung. 59 (2009), 213–227.
44. Lagorce, P, Perez, Y, Ortiz, J, et al. Assay method for the carboxylic acid metabolite of clopidogrel in human plasma by gas chromatographymass spectrometry. J Chromatogr B Biomed Sci Appl. 720 (1998), 107–117.
45. Souri, E, Jalalizadeh, H, Kebriaee-Zadeh, A, et al. Validated HPLC method for determination of carboxylic acid metabolite of clopidogrel in human plasma and its application to a pharmacokinetic study. Biomed Chromatogr. 20 (2006), 1309–1314.
46. Ksycinska, H, Rudzki, P, BukowskaKiliszek, M, Determination of clopidogrel metabolite (SR26334) in human plasma by LC-MS. J Pharm Biomed Anal. 41 (2006), 533–539.
47. Bahrami, G, Mohammadi, B, Sisakhtnezhad, S, High-performance liquid chromatographic determination of inactive carboxylic acid metabolite of clopidogrel in human serum: Application to a bioequivalence study. J Chromatogr B Analyt Technol Biomed Life Sci. 864 (2008), 168–172.
48. Singh, SS, Sharma, K, Barot, D, et al. Estimation of carboxylic acid metabolite of clopidogrel in Wistar rat plasma by HPLC and its application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 821 (2005), 173–180.
49. US Food and Drug Administration. Guidance for Industry. Bioavailability and bioequivalence studies for orally administered drug productsgeneral considerations. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070124.pdf Accessed October 15, 2009.
50. Nirogi, RV, Kandikere, VN, Shukla, M, et al. Quantification of clopidogrel in human plasma by sensitive liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 20 (2006), 1695–1700.
51. Robinson, A, Hills, J, Neal, C, Leary, AC, The validation of a bioanalytical method for the determination of clopidogrel in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 848 (2007), 344–354.
52. Heestermans, AA, van Werkum, JW, Taubert, D, et al. Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thromb Res. 122 (2008), 776–781.
53. Srinivas, NR, Mamidi, RN, Bioanalytical considerations for compounds containing free sulfhydryl groups. Biomed Chromatogr. 17 (2003), 285–291.
54. Nirogi, RV, Kandikere, VN, Mudigonda, K, Effect of food on bioavailability of a single dose of clopidogrel in healthy male subjects. Arzneimittelforschung. 56 (2006), 735–739.
55. Gurbel, PA, Bliden, KP, Hiatt, BL, O'Connor, CM, Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 107 (2003), 2908–2913.
56. Gurbel, PA, Tantry, US, Drug insight: Clopidogrel nonresponsiveness. Nat Clin Pract Cardiovasc Med. 3 (2006), 387–395.
57. Gurbel, PA, Bliden, KP, Hayes, KM, et al. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol. 45 (2005), 1392–1396.
58. Mobley, JE, Bresee, SJ, Wortham, DC, et al. Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization. Am J Cardiol. 93 (2004), 456–458.
59. Muller, I, Besta, F, Schulz, C, et al. Prevalence of clopidogrel non- responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost. 89 (2003), 783–787.
60. Brandt, JT, Close, SL, Iturria, SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost. 5 (2007), 2429–2436.
61. Farid, NA, Payne, CD, Small, DS, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 81 (2007), 735–741.
62. Suh, JW, Koo, BK, Zhang, SY, et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel [published correction appears in CMAJ. 2006;175:64]. CMAJ. 174 (2006), 1715–1722.
63. Nguyen, TA, Diodati, JG, Pharand, C, Resistance to clopidogrel: A review of the evidence. J Am Coll Cardiol. 45 (2005), 1157–1164.
64. Ford, NF, Clopidogrel resistance: Pharmacokinetic or pharmacogenetic?. J Clin Pharmacol. 49 (2009), 506–512.
65. Taubert, D, von Beckerath, N, Grimberg, G, et al. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther. 80 (2006), 486–501.
66. Marzo, A, Balant, LP, Bioequivalence. An updated reappraisal addressed to applications of interchangeable multi-source pharmaceutical products. Arzneimittelforschung. 45 (1995), 109–115.